The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Focused Atorvastatin Therapy in Managed-Care Patients With Coronary Heart Disease and CKD
Abstract
Background This post hoc analysis of the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) Study investigates the effect of focused atorvastatin therapy versus usual care on cardiovascular outcomes in patients with coronary heart disease (CHD) with and without chronic kidney disease (CKD).Study design Prospective randomized open-label; median follow-up, 54.3 months.Setting & participants Managed care or Veterans Affairs facilities; 2,442 patients with CHD with dyslipidemia; mean age, 61.6 years.Intervention Focused atorvastatin therapy to a low-density lipoprotein cholesterol goal of less than 80 mg/dL or maximum dose of 80 mg/d versus usual care as deemed appropriate by patients' regular physicians.Predictor Baseline estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease Study equation of less than 60 mL/min/1.73 m(2) (patients with CKD) and 60 mL/min/1.73 m(2) or greater (patients without CKD).Outcomes & measurements The primary end point was time to first cardiovascular event. Change from baseline eGFR was assessed in 1,768 patients with follow-up renal data.Results At baseline, 579 patients (23.7%) had CKD: 31.6% of these patients experienced a primary cardiovascular event during the study versus 23.6% of patients without CKD (hazard ratio [HR], 1.41; 95% confidence interval [CI], 1.18 to 1.68; P < 0.001). Compared with usual care, atorvastatin therapy reduced the relative risk of a primary outcome by 28% in patients with CKD (HR, 0.72; 95% CI, 0.54 to 0.97; P = 0.02) and 11% in patients without CKD (HR, 0.89; 95% CI, 0.74 to 1.07; P = 0.3) (P for treatment by CKD interaction = 0.2). There was no decrease in eGFR in atorvastatin-treated patients during the course of the study.Limitations Follow-up of atorvastatin patients was restricted to every 6 months; interim data were unavailable for usual-care patients.Conclusions Patients with CHD and CKD are at increased risk of cardiovascular events. Compared with usual care, focused atorvastatin treatment decreased cardiovascular risk for established patients in real-world settings, with no significant difference in treatment effects observed between patients with and without CKD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, suppressive effects on cerebrovascular diseases were not demonstrated.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [771]
In the citing paper
“These analyses have reported that statin use suppresses cardiovascular events in patients with mild CKD and an eGFR < 75 mL/min/1.73 m2 771, 772).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [771]
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Prevalence of Chronic Kidney Disease in the United States
Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895
Clinical epidemiology of cardiovascular disease in chronic renal disease
Rn, F., Parfrey, P. S., & Sarnak, M. J. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v32.pm9820470 · Cited by 3,960
Sarnak, M. J., Levey, A. S., Schoolwerth, A. C., Coresh, J., Culleton, B., Hamm, L. L., McCullough, P. A., Kasiske, B. L., Kelepouris, E., Klag, M. J., et al. (2003) · Circulation · doi:10.1161/01.cir.0000095676.90936.80 · Cited by 3,768
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
(2000) · Journal of the American Society of Nephrology · Cited by 1,718
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research; Group, T. A. O. A. C. F. T. A. C. R. G. (2002) · JAMA · doi:10.1001/jama.288.23.2998 · Cited by 1,328
Levey, A. S., Beto, J. A., Coronado, B., Eknoyan, G., Rn, F., Kasiske, B. L., Klag, M. J., Mailloux, L., Manske, C., Kb, M., et al. (1998) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(98)70145-3 · Cited by 944
Statins for Improving Renal Outcomes
Sandhu, S., Wiebe, N., Fried, L. F., & Tonelli, M. A. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006010012 · Cited by 475
Flagged first, then by citations
Cited by
Sorted by citations
Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813
Palmer, S. C., Craig, J. C., Navaneethan, S. D., Tonelli, M., Pellegrini, F., & Strippoli, G. F. M. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-4-201208210-00007 · Cited by 359
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Palmer, S. C., Navaneethan, S. D., Craig, J. C., Johnson, D. W., Perkovic, V., Hegbrant, J., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007784.pub2 · Cited by 336
Juusola, J. L. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-8-201204170-00004 · Cited by 244
Qaseem, A., HOPKINS, R. H., Sweet, D. E., Starkey, M., & Shekelle, P. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-12-201312170-00726 · Cited by 189
Dyslipidemia Associated with Chronic Kidney Disease
Tsimihodimos, V., Mitrogianni, Z., & Elisaf, M. (2011) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401105010041 · Cited by 183
Lipid-Lowering Therapy in Persons With Chronic Kidney Disease
Upadhyay, A., Earley, A., Lamont, J. L., Haynes, S. M., Wanner, C., & Balk, E. M. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-4-201208210-00005 · Cited by 166
Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis
Su, X., Zhang, L., Lv, J., Wang, J., Hou, W., Xie, X., & Zhang, H. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.01.016 · Cited by 164
Stage IV Chronic Kidney Disease
Abboud, H. E., & Henrich, W. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmcp0906797 · Cited by 170
Fink, H. A., Ishani, A., Taylor, B. C., Greer, N. L., MacDonald, R., Rossini, D., Sadiq, S., Lankireddy, S., Kane, R. L., & Wilt, T. J. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-8-201204170-00008 · Cited by 153
Chronic kidney disease and diabetes
Pyram, R., Kansara, A., Banerji, M. A., & Loney‐Hutchinson, L. (2011) · Maturitas · doi:10.1016/j.maturitas.2011.11.009 · Cited by 102
Sanguankeo, A., Upala, S., Cheungpasitporn, W., Ungprasert, P., & Knight, E. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132970 · Cited by 104
Barylski, M., Nikfar, S., Mikhailidis, D. P., Toth, P. P., Salari, P., Ray, K. K., Pencina, M. J., Rizzo, M., Rysz, J., Abdollahi, M., et al. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.03.007 · Cited by 98
Statins and Multiple Noncardiovascular Outcomes
He, Y., Li, X., Gašević, D., Brunt, E., McLachlan, F., Millenson, M. E., Timofeeva, M. N., Ioannidis, J. P. A., Campbell, H. J., & Τheodoratou, E. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0808 · Cited by 97
Statins, inflammation and kidney disease
Krane, V., & Wanner, C. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.62 · Cited by 89
Kuznik, A., Mardekian, J., & Tarasenko, L. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-132 · Cited by 86
Nikolić, D., Banach, M., Nikfar, S., Salari, P., Mikhailidis, D. P., Toth, P. P., Abdollahi, M. R., Ray, K. K., Pencina, M. J., Małyszko, J., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.08.060 · Cited by 80
Yamamoto, S., Zuo, Y., Ma, J., Yancey, P. G., Hunley, T. E., Motojima, M., Fogo, A. B., Linton, M. F., Fazio, S., Ichikawa, I., et al. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq759 · Cited by 74
Sakaeda, T., Kadoyama, K., & Okuno, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028124 · Cited by 74
Visconti, L., Benvenga, S., Lacquaniti, A., Cernaro, V., Bruzzese, A., Conti, G., Buemi, M., & Santoro, D. (2016) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2016.08.002 · Cited by 75
Fassett, R. G., Robertson, I. K., Ball, M. J., GERAGHTY, D. P., & Coombes, J. S. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.07.053 · Cited by 70
Esmeijer, K., Dekkers, O. M., de Fijter, J. W., Dekker, F. W., & Hoogeveen, E. K. (2019) · Scientific Reports · doi:10.1038/s41598-019-53064-x · Cited by 73
Zhang, Z., Wu, P., Zhang, J., Wang, S., & Zhang, G. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.005 · Cited by 65
Clinical therapeutic strategies for early stage of diabetic kidney disease
Kitada, M. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i3.342 · Cited by 57
Meta-analysis of statins in chronic kidney disease: who benefits?
Messow, C., & Isles, C. (2017) · QJM · doi:10.1093/qjmed/hcx040 · Cited by 54
Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives
Theofilis, P., Vordoni, A., Koukoulaki, M., Vlachopanos, G., & Kalaitzidis, R. (2021) · American Journal of Nephrology · doi:10.1159/000518456 · Cited by 56
Athyros, V. G., Katsiki, N., Karagiannis, A. I., & Mikhailidis, D. P. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1053464 · Cited by 48
Statin Use and the Risk of Kidney Disease With Long-Term Follow-Up (8.4-Year Study)
Acharya, T., Huang, J., Tringali, S., Frei, C. R., Mortensen, E. M., & Mansi, I. A. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.11.031 · Cited by 49
Yan, Y., Qiu, B., Wang, J., Deng, S., Wu, L., Jing, X., Du, J., Liu, Y., & She, Q. (2015) · BMJ Open · doi:10.1136/bmjopen-2014-006886 · Cited by 48
The Role of Statins in Chronic Kidney Disease
Kalaitzidis, R., & Elisaf, M. (2011) · American Journal of Nephrology · doi:10.1159/000330355 · Cited by 48
Zhao, L., Li, S., & Gao, Y. (2021) · Renal Failure · doi:10.1080/0886022x.2021.1915799 · Cited by 47
Zhang, X., Xiang, C., Zhou, Y., Jiang, A., Qin, Y., & He, J. (2014) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-14-19 · Cited by 37
Serum Lipid Profiles, Lipid Ratios and Chronic Kidney Disease in a Chinese Population
Zhang, L., Yuan, Z., Chen, W., Chen, S., Liu, X., Liang, Y., Shao, X., & Zou, H. (2014) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph110807622 · Cited by 36
Natsuaki, M., Furukawa, Y., Morimoto, T., Sakata, R., & Kimura, T. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.07.021 · Cited by 35
Amarenco, P., Callahan, A. S., III, Campese, V. M., Goldstein, L. B., Hennerici, M. G., Messig, M., Sillesen, H. H., Welch, K. M. A., Wilson, D. J., & Zivin, J. A. (2014) · Stroke · doi:10.1161/strokeaha.114.005832 · Cited by 33
Self-citationRutter, M. K., Prais, H., Charlton-Menys, V., Gittins, M., Roberts, C., Davies, R. R., Moorhouse, A., Jinadev, P., France, M. W., Wiles, P. G., et al. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03139.x · Cited by 33
DEEDWANIA, P. C., Stone, P. H., Fayyad, R. S., Laskey, R. E., & Wilson, D. J. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0328-z · Cited by 32
Self-citationEffects of Rosuvastatin and Atorvastatin on Renal Function
Wu, Y., Wang, Y., An, C., Dong, Z., Liu, H., Zhang, Y., Zhang, M., & An, F. (2012) · Circulation Journal · doi:10.1253/circj.cj-11-1385 · Cited by 32
Clinical assessment and management of dyslipidemia in patients with chronic kidney disease
Nitta, K. (2012) · Clinical and Experimental Nephrology · doi:10.1007/s10157-012-0655-x · Cited by 32
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Tunnicliffe, D. J., Palmer, S. C., Cashmore, B. A., Saglimbene, V. M., Krishnasamy, R., Lambert, K., Johnson, D. W., Craig, J. C., & Strippoli, G. F. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007784.pub3 · Cited by 39
Statins in chronic kidney disease and kidney transplantation
Kassimatis, T. I., & Goldsmith, D. J. A. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.06.011 · Cited by 32
DiNicolantonio, J. J., Lavie, C. J., Serebruany, V. L., & O’Keefe, J. H. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.01.2620 · Cited by 32
Łuczak, M., Formanowicz, D., Marczak, Ł., Pawliczak, E., Wanic-Kossowska, M., Figlerowicz, M., & Stobiecki, M. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-014-0378-8 · Cited by 30
Urinary NGAL-Positive Acute Kidney Injury and Poor Long-term Outcomes in Hospitalized Patients
Singer, E., Schrezenmeier, E. V., Elger, A., Seelow, E., Krannich, A., Luft, F. C., & Schmidt-Ott, K. M. (2016) · Kidney International Reports · doi:10.1016/j.ekir.2016.07.003 · Cited by 31
Dohi, T., Miyauchi, K., Okazaki, S., Yokoyama, T., Tamura, H., Kojima, T., Yokoyama, K., Kurata, T., & Daida, H. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq820 · Cited by 26
Holme, I., Fayyad, R. S., Færgeman, O., Kastelein, J. J. P., OLSSON, A. G., Tikkanen, M. J., Larsen, M. L., Lindahl, C., Holdaas, H., Pedersen, T. R., et al. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02176.x · Cited by 25
Self-citationHerrera‐Gómez, F., Chimeno, M. M., Martín-García, D., Lizaraso-Soto, F., Maurtua-Briseño-Meiggs, Á., Grande-Villoría, J., Bustamante‐Munguira, J., Alamartine, É., Vilardell, M., Sangrador, C. O., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-45431-5 · Cited by 26
Statin Use and Survival After Acute Kidney Injury
Brar, S. K., Ye, F., James, M. T., Hemmelgarn, B. R., Klarenbach, S. W., & Pannu, N. (2016) · Kidney International Reports · doi:10.1016/j.ekir.2016.08.009 · Cited by 24
Pontremoli, R., Bellizzi, V., Bianchi, S., Bigazzi, R., Cernaro, V., Vecchio, L. D., Nicola, L. D., Leoncini, G., Mallamaci, F., Zoccali, C., et al. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00707-2 · Cited by 28
Hamasaki, Y., Doi, K., Okamoto, K., Ijichi, H., Seki, G., Maeda-Mamiya, R., Fujita, T., & Noiri, E. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2012.71 · Cited by 23
Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk
Theofilis, P., Vlachakis, P. K., Karakasis, P., & Kalaitzidis, R. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01290-2 · Cited by 26
Statins and Cardiovascular Disease Outcomes in Chronic Kidney Disease: Reaffirmation vs. Repudiation
Obialo, C. I., Ofili, E., & Norris, K. C. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15122733 · Cited by 22
Ho, J. E., Waters, D. D., Kean, A. J., Wilson, D. J., DeMicco, D. A., Breazna, A., Wun, C., DEEDWANIA, P. C., & Khush, K. K. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.02.019 · Cited by 21
Self-citationBansal, N., Hsu, C., Chandra, M., Iribarren, C., Fortmann, S. P., Hlatky, M. A., & Go, A. S. (2011) · BMC Nephrology · doi:10.1186/1471-2369-12-44 · Cited by 20
Fassett, R. G., Robertson, I. K., Ball, M. J., GERAGHTY, D. P., Cardinal, J. W., & Coombes, J. S. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr193 · Cited by 19
Statins in Chronic Kidney Disease: Cardiovascular Risk and Kidney Function
DEEDWANIA, P. C. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.01.2722 · Cited by 18
Cálice-Silva, V., Muenz, D. G., Wong, M., McCullough, K. P., Charytan, D. M., Reichel, H., Robinson, B. M., Stengel, B., Massy, Z. A., Pecoits‐Filho, R., et al. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01833-z · Cited by 18
Statin Use in Patients with Diabetes and Kidney Disease: The Japanese Experience
Koya, D., & Campese, V. M. (2013) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.16261 · Cited by 18
Managing advanced chronic kidney disease: A primary care guide
Sakhuja, A., Hyland, J., & Simon, J. F. (2014) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.81a.13046 · Cited by 17
Markossian, T. W., Burge, N. J., Ling, B., Schneider, J., Pacold, I. V., Bansal, V., Leehey, D. J., Stroupe, K. T., Chang, A. R., & Kramer, H. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.12.030 · Cited by 16
Dasari, T. W., Cohen, D. J., Kleiman, N. S., Keyes, M. J., Yen, C.-H., Hanna, E. B., & Saucedo, J. F. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.11.006 · Cited by 17
Pharmacotherapy of end-stage renal disease
Schmid, H., Schiffl, H., & Lederer, S. R. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903544494 · Cited by 15
Rysz, J., Gluba-Brzózka, A., Banach, M., & Więcek, A. (2015) · International Urology and Nephrology · doi:10.1007/s11255-015-0937-9 · Cited by 14
LDL-cholesterol lowering and renal outcomes
Waters, D. D. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000176 · Cited by 14
Guo, B., Kuo, K., Huang, J., Chen, C.-H., Tarng, D., & Lee, T. (2023) · Antioxidants · doi:10.3390/antiox12020477 · Cited by 14
Naganuma, T., Tsujita, K., Mitomo, S., Ishiguro, H., Basavarajaiah, S., Sato, K., Kobayashi, T., Obata, J., Nagamatsu, S., Yamanaga, K., et al. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.02.032 · Cited by 13
Takagi, H., & Umemoto, T. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.06.107 · Cited by 12
Elkoumi, O., Elkoumi, A., Elbairy, M., Irfan, H., Hageen, A., Beddor, A., Khalid, N., Mahmoud, M., Emara, A., Alkhazaleh, U., et al. (2025) · American Journal of Cardiology · doi:10.1016/j.amjcard.2025.07.010 · Cited by 9
Jenkins, M. G., & Goldsmith, D. J. A. (2012) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328353b988 · Cited by 11
Peng, M., Dong, H., Jiang, X., Che, W., Zou, Y., Zhang, Y., & Liu, L. (2019) · Journal of Cardiology · doi:10.1016/j.jjcc.2019.04.010 · Cited by 11
Teramoto, T., Sasaki, J., Ishibashi, S., Birou, S., Daida, H., Dohi, S., Egusa, G., Hiro, T., Hirobe, K., Iida, M., et al. (2013) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.19158 · Cited by 11
Reducing morbidity and mortality in high risk patients with statins
DEEDWANIA, P. C., & Singh, V. N. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3389 · Cited by 10
Kumthekar, G. V., Mondhe, S., Hedau, S., Naidu, S., & Chakravarthi, R. M. (2022) · Indian Journal of Nephrology · doi:10.4103/ijn.ijn_30_20 · Cited by 9
Liao, G., Wang, X., Li, Y., Chen, X., Huang, K., Bai, L., Ye, Y., & Peng, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010006 · Cited by 10
Lipid lowering in renal disease
Kennard, A. L., & Singer, R. F. (2017) · Australian Prescriber · doi:10.18773/austprescr.2017.047 · Cited by 9
Effect of statins on cardiovascular complications in chronic kidney disease patients
Hwang, S. D., Kim, K., Kim, Y. J., Lee, S. W., Lee, J. H., & Song, J. H. (2020) · Medicine · doi:10.1097/md.0000000000020061 · Cited by 9
Song, E. J., Ahn, S., Min, S., Ha, J., & Oh, G. T. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.3.136 · Cited by 8
Statin Effects in CKD: Is There a “Point of No Return”?
Wanner, C. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.02.002 · Cited by 8
Kuo, F. Y., Huang, W., Tang, P., Cheng, C.-C., Chiang, C., Lin, H.-C., Chuang, T.-J., Wann, S., Mar, G.-Y., Liu, C., et al. (2021) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-137292 · Cited by 7
Garofalo, C., Borrelli, S., Liberti, M. E., Chiodini, P., Peccarino, L., Pennino, L., Polese, L., Gregorio, I. D., Scognamiglio, M., Ruotolo, C., et al. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.09.014 · Cited by 8
Changes over the last decade in carotid atherosclerosis in patients with end-stage kidney disease
Asakawa, T., Hayashi, T., Tanaka, Y., Joki, N., & Hase, H. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.04.784 · Cited by 7
Brar, A., Santana, J., Salifu, M., & Brown, C. D. (2019) · Dyslipidemia · doi:10.5772/intechopen.82831 · Cited by 4
Serum lipid profiles in patients with chronic kidney disease in a Saudi population
Aljabri, K. S. (2019) · Endocrinology&Metabolism International Journal · doi:10.15406/emij.2019.07.00239 · Cited by 6
Zarei, L., Rad, S. M., & Fard, A. A. (2019) · PubMed Central · doi:10.30466/vrf.2019.74079.1996 · Cited by 5
Wieczorek‐Surdacka, E., Świerszcz, J., & Surdacki, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020106 · Cited by 5
Айтбаев, К. А., Murkamilov, I. T., & Fomin, V. V. (2019) · Kardiologiia · doi:10.18087/cardio.2019.2.10231 · Cited by 5
Khambatta, S., Farkouh, M. E., Wright, R. S., Reeder, G. S., McCullough, P. A., Smars, P. A., Hickson, L. J., & Best, P. J. M. (2012) · Translational research · doi:10.1016/j.trsl.2011.12.006 · Cited by 5
HMG-CoA Reductase Inhibitors in Chronic Kidney Disease
Olyaei, A., Steffl, J., MacLaughlan, J., Trabolsi, M., Quadri, S., Abbasi, I., & Lerma, E. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0041-4 · Cited by 4
Lipid lowering in patients with chronic kidney disease: a SHARP turn in the wrong direction?
Berthold, H. K., Krone, W., Erdmann, E., & Gouni‐Berthold, I. (2011) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/1741826711423116 · Cited by 5
Vedamurthy, D., Sagheer, U., Tyagi, M., Maki, K. C., & Kalra, D. K. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.09.014 · Cited by 5
Lipid-Lowering Therapy in Individuals With CKD: Lessons Learned From SHARP
Upadhyay, A., & Weiner, D. E. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.09.008 · Cited by 3
Changsirikulchai, S., Sangthawan, P., Janma, J., Sripaiboonkij, N., Rattanamongkolgul, S., & Thinkhamrop, B. (2016) · Nephrology · doi:10.1111/nep.12922 · Cited by 3
Nozue, T., Yamamoto, S., Tohyama, S., Fukui, K., Umezawa, S., Onishi, Y., Kunishima, T., Hibi, K., Terashima, M., Michishita, I., et al. (2012) · Nephrology · doi:10.1111/j.1440-1797.2012.01628.x · Cited by 3
Zhang, Y., Zhai, G., Wang, J., & Zhou, Y. (2022) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296221081848 · Cited by 3
Sorrentino, M. J. (2010) · Cardiology Clinics · doi:10.1016/j.ccl.2010.04.009 · Cited by 2
Bai, X., Jiang, J., Tu, S., & Zhang, W. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202301511 · Cited by 1
Huang, Y., Yang, A., Shi, M., Wu, H., Ke, C., Yu, J., Lui, J. N., Kong, A. P., Ma, R. C., Chan, J., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103712 · Cited by 1
Mal, G. S., & Kuznetsov, A. A. (2022) · Innovative medicine of Kuban · doi:10.35401/2541-9897-2022-25-2-14-21 · Cited by 3
Atorvastatin in patients with coronary artery disease and left ventricular systolic dysfunction
Филиппов, Е. В., & Moseichuk, K. A. (2019) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2019-16-28-33 · Cited by 1
Masuo, K. (2015) · InTech eBooks · doi:10.5772/59862 · Cited by 2
Metadata
- Authors
- Koren, M. J., Davidson, M. H., Wilson, D. J., Fayyad, R. S., Zuckerman, A., & Reed, D. P.
- Affiliations
- Jacksonville Center for Clinical Research (US)
- University of Chicago (US)
- Pfizer (United States) (US)
- Corresponding author
- Koren, Michael J.
- Venue
- American Journal of Kidney Diseases
- Publisher
- Elsevier BV
- Published
- 2009-05
- Volume
- 53
- Issue
- 5
- Pages
- 741-750
- ISSN
- 0272-6386 (ISSN-L)
- OpenAlex
- W1979397038
- Cited by
- 115
- References
- 28
- Citations by year
- 2025: 4 · 2024: 4 · 2023: 5 · 2022: 4 · 2021: 6 · 2020: 4 · 2019: 8 · 2018: 5 · 2017: 3 · 2016: 8 · 2015: 10 · 2014: 8 · 2013: 9 · 2012: 12
- FWCI
- 12.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Kidney Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- atorvastatin, coronary artery disease, chronic kidney disease, LDL cholesterol lowering, cardiovascular events, estimated glomerular filtration rate, statin therapy, managed care, dyslipidemia, renal safety, veterans, cardiovascular risk reduction, renal function preservation, cardiovascular risk stratification
- MeSH terms
- Atorvastatin, Aged, Coronary Disease, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Glomerular Filtration Rate, Health Maintenance Organizations, Heptanoic Acids, Humans, Kidney Failure, Chronic, Cholesterol, LDL, Male, Middle Aged, Prospective Studies, Pyrroles, Time Factors, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
